Current Trends In Vaccine R&D Show Investments Lacking For TB, HIV, Malaria Products, Duke Analysis Says

Homeland Preparedness News: Financial study reveals global health investment neglects TB, HIV, malaria vaccines
“Despite the deadly reach of diseases like tuberculosis (TB), HIV, and malaria, the world is not likely to develop vaccines to fight them, according to a financial analysis of the current research and development pipeline. The analysis was conducted by Duke University’s Center for Policy Impact in Global Health, following a review of 538 candidate products for 35 neglected diseases. Using that information, they applied a financial modeling tool known as Portfolio-to-Impact (P2I) to estimate the costs and likelihood a product would come to pass…” (Galford, 9/6).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.